Navigation Links
Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors
Date:8/29/2014

BOSTON, Aug. 29, 2014 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostics medical device company based in Boston announced today that T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd  was appointed to the company's Board of Directors.

"Teo Forcht Dagi is an experienced leader with a distinguished career in neurosurgery, medical innovation and venture capital," said Remis Bistras, President and CEO of Vittamed. "We are extremely delighted to add his clinical, strategic, and entrepreneurial expertise to our Board."

Dr. Dagi is a board certified neurosurgeon trained at the Massachusetts General Hospital. He holds faculty appointments at Harvard Medical School and Queen's University Belfast. He served as President of the Georgia Neurosurgical Society and as a Director of the American Association of Neurological Surgeons.  He has sat on numerous public and private boards, has been involved in many start-ups and early stage companies, and served as a partner at and advisor to prominent venture capital funds.  

"I am honored to join Vittamed at this exciting time in its history," said Dr. Dagi.  "With the recent CE mark approval for both its products and multiple near-term commercial opportunities, I look forward to helping Vittamed achieve its mission of delivering non-invasive neuromonitoring and diagnostics to patients with unmet medical needs."

He received an AB from Columbia, and an MD and MPH from Johns Hopkins. He holds an MBA with distinction from Wharton and was awarded a DMedSc (Honoris Causae) from Queen's University Belfast for contributions to medicine and public service. 

About Vittamed
Vittamed is a Boston-based company with R&D operations in Lithuania. Using ultrasound based technology, it has developed a suite of clinically proven and validated devices.  The Vittamed 205 is a non-invasive Intracranial Pressure (ICP) meter and the Vittamed 505 is a non-invasive Cerebrovascular Perfusion and Autoregulation monitoring device.  Multiple prospective clinical trials with several hundred patients have proven that the Vittamed devices deliver reliable, clinically acceptable, accurate and precise results as compared to today's standard of care using invasive intraventricular and lumbar puncture ICP measurements.  Recently Vittamed received CE mark for its both devices and is preparing for commercialization in the EU as well as 510 (k) filing in the US.

For more information, please visit www.vittamed.com


'/>"/>
SOURCE Vittamed Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
2. Meditope Biosciences Appoints Prominent Scientific Advisory Board
3. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
4. Sanomedics Signs Definitive Agreement for Acquisition of a prominent Texas based Sleep Services company.
5. Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
6. Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
7. La Jolla Neurosurgeon Introduces Cutting-Edge Surgery for Scoliosis Patients
8. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
9. Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures
10. Vivex Biomedical and Akron Biotech: Collaborative Venture in Regenerative Medicine
11. Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):